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Alterations in the stoichiometric balance between
members of Bcl-2 and Fas apoptotic pathway could
lead to thepathogenesis of systemic lupus erythema-
tosus (SLE). We showed that patients with SLE dis-
played increased expression in antiapoptotic mem-
bers of the Bcl-2 and Fas apoptotic pathways in
isolatedmononuclear cells. Further, mice (Bcl2l11/
Faslpr/lpr) lacking the Bcl-2 pro-apoptotic member,
Bim (Bcl2l11/) and and with an lpr mutation in the
gene encoding Fas (Faslpr/lpr) developed severe
SLE-like disease by 16 weeks of age unlike
Bcl2l11/ or Faslpr/lpr mice. Bcl2l11/Faslpr/lpr
antigen-presenting cells (APCs) were markedly acti-
vated, and their numbers were increased in lymphoid
tissues and in kidneys, yet numerous TUNEL-positive
cells were observed in glomeruli of Bcl2l11/
Faslpr/lprmice. These data demonstrate that dysregu-
lation of the Bcl-2 or Fas pathways can alter the func-
tion of APCs, thereby leading to SLE pathogenesis.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a multifactorial, multige-
netic autoimmune disease that is primarily defined by increased
incidence of autoantibodies that contribute to severe end-organ
damage to the spleen, liver, joints, central nervous system,
cardiovascular system, and kidneys (Munoz et al., 2005). Inflam-
mation resulting from deposited immune complexes can lead to
glomerulonephritis, dermatitis, serositis, and vasculitis (Liu and
Mohan, 2006). Apoptotic cells might be a source of autoantigens
(Cohen, 2006). Thus, a defect in apoptosis or a reduction in the
clearance of apoptotic cells could promote SLE pathogenesis.
In mammals, there are two pathways of apoptosis: extrinsic
and intrinsic (Strasser et al., 2000). In the extrinsic apoptosis
pathway, death ligands bind to their cognate death receptors
on the cell surface, as in the case of Fas ligand (FasL) and Fas.
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ciated death domain (FADD) and procaspase-8 to the C terminus
of the death receptor. Recruitment of multiple procaspase-8
molecules leads to autocatalysis of caspase-8 and subsequent
activation of caspase-3 and caspase-7, which mark the begin-
ning of the degradative phase of apoptosis. The intrinsic apopto-
sis pathway is mediated by the Bcl-2 protein family. Members of
this family are defined by their homology to the Bcl-2 protein on
the basis of the presence of up to four Bcl-2 homology (BH) do-
mains that are crucial for dimerization between family members
(Strasser, 2005). The Bcl-2 family has both antiapoptotic and
proapoptotic members. Antiapoptotic members such as Bcl-2,
Bcl-xL, Mcl-1, A1, and Bcl-w contain three or all four of the BH
domains, whereas the proapoptotic family members are subdi-
vided into multi-BH domain (BH1-3) proteins such as Bax and
Bak and BH3-only proteins such as Bim, Bid, Bad, Noxa, and
Puma (Strasser, 2005; Strasser et al., 2000). The intrinsic apopto-
tic pathway is largely dependent on a sequence of events occur-
ring at or within the mitochondria. Both the extrinsic and intrinsic
apoptosis pathways have been shown to play a role in the devel-
opment of SLE that is strain and background dependent.
Fas mutant mice (Faslpr/lpr) on the MRL background (MRL.
Faslpr/lpr) develop systemic vasculitis, arthritis, early-onset
splenomegaly, progressive lymphadenopathy, andglomerulone-
phritis includingmononuclear cell infiltration, crescent formation,
and increased presence of autoantibodies in the kidney (Cohen
and Eisenberg, 1991; Nagata and Suda, 1995), as well as 50%
mortality by 6 months of age (Theofilopoulos and Dixon, 1985).
However, on the C57BL/6 background, the development of
disease is subdued, with reduced lymphoproliferation, later
onset of autoantibody production, and few to no renal defects
(Theofilopoulos and Dixon, 1985). Furthermore, MRL.
Faslpr/lpr and C57BL/6.Faslpr/lpr mice display a large number of
CD4CD8-CD3+B220+ T lymphocytes in the periphery (Theofilo-
poulos and Dixon, 1985; Vidal et al., 1998). Mice lacking Bim de-
velop lymphadenopathy and splenomegaly, display increased
amounts of circulating autoantibodies, and accumulate immuno-
globin G (IgG)-secreting plasma cells resulting in hypergamma-
globulinemia even on a C57BL/6 background (Bouillet et al.,
1999; Hughes et al., 2006). Approximately half of Bcl2l11/
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lonephritis, characterized by increased serum concentrations of
urea, glomerular hypercellularity, increased mesangial matrix,
and deposits of immune complexes (Bouillet et al., 1999). It has
also been shown that Bim plays an important role in the mainte-
nance of anergic B cells and that the loss of Bim can lead to the
survival of autoreactive B cells that would normally have been
eliminated by anergy (Oliver et al., 2006). In addition, Bim is
required for negative selection of T cells (Bunin et al., 2005;
Villunger et al., 2004). These data suggest that both the intrinsic
and extrinsic apoptosis pathways play important roles in the
development of SLE-like disease. However, contribution of both
pathways to the development of SLE-like disease is unknown.
Here, we examined mononuclear cells from patients with SLE
and showed that they have an antiapoptotic signature. To under-
stand the significance in the skewing the ratio of antiapoptotic
to proapoptotic members in SLE development, we generated
mice deficient for both the extrinsic death receptor Fas and the
proapoptotic Bcl-2 family member Bim (Bcl2l11/Faslpr/lpr).
Bcl2l11/Faslpr/lpr mice displayed enhanced and accelerated
splenomegaly and lymphadenopathy, including an increase in
the number of hematopoietic cells. Furthermore, Bcl2l11/
Faslpr/lpr mice showed severe damage to the glomeruli of the
kidneys that was associated with an increase in circulating and
deposited autoantibodies. Bcl2l11/Faslpr/lpr mice had an in-
crease in interglomerular proliferation and displayed an en-
hanced number of macrophages surrounding the glomeruli
and an increased number of TUNEL+ cells within the glomeruli.
Taken together, these data suggest that deficiency in Bim and
Fas is sufficient to induce a full blown lupus-like disease even
on a resistant background. Thus, therapies that target both
Bim and Fas might be more effective at controlling or inducing
remission of SLE.
RESULTS
To date, the critical factors involved in the apoptotic pathways
and their influence on the development of SLE are unknown.
Further, the interpretation of studies in mice examining the direct
role of proapoptotic genes in SLE are complicated by the strain
and background of the mice. To identify the potential apoptotic
genes involved in SLE, we performed a microarray analysis on
SLE patients and healthy controls. Previous studies have
suggested that type I interferon is critical for SLE pathogenesis
(Bennett et al., 2003); as such, all patients with SLE displayed
an increase in expression of MX1, an interferon-inducible gene.
We observed that expression of genes encoding antiapoptotic
members of the Bcl-2 family including BCL2A1 (1.8-fold; p <
0.04) and MCL1 (1.5-fold; p < 0.02) were enhanced in myeloid
cells from a subset of SLE patients as compared to healthy con-
trols (Figure 1A). There was no difference in the amounts of
expression in BCL2A1 andMCL1 from isolated T and B lympho-
cyte populations. Additionally, the expression of CFLAR, the
gene encoding FLIP, a naturally occurring inhibitor of the Fas
death pathway, was markedly elevated in myeloid cells (1.9-
fold; p < 0.007), T lymphocytes (1.4-fold; p < 0.04), and B lym-
phocytes (2.1-fold; p < 0.04) from subset of SLE patients as
compared to healthy controls (Figures 1A–1C). Taken together,
these data demonstrate a correlation between the increase inexpression of MX1 with the expression of CFLAR and MCL1 in
B cells (CFLAR: r = 0.52, p < 0.01; MCL1: r = 0.43, p < 0.04)
and myeloid cells (r = 0.52, p < 0.01; r = 0.68, p < 0.0006), and
BCL2A1 (r = 0.53, p < 0.01) in myeloid cells and the SLE pheno-
type. Given the previously established relationship betweenMX1
expression and disease severity (Bennett et al., 2003), these data
further suggest a connection between increased antiapoptotic
gene expression and SLE severity.
Bcl2l11/Faslpr/lpr Mice Display Severe Splenomegaly
and Lymphadenopathy
To understand the significance of the differential increase in the
expression of genes that are involved in the Bcl-2 and Fas path-
ways, we focused on mice lacking components of the Bcl-2 and
Fas pathways, specifically Bim and Fas. Previous studies with
mice lacking the antiapoptotic Bcl-2 proteins have been ham-
pered by early lethality and mice that overexpress antiapoptotic
Bcl-2 family members in a cell-type-specific manner have either
failed to display or show a mild autoimmune disease phenotype
(Hughes et al., 2006). To date, only mice lacking Bim have been
shown to develop autoimmune disease on a mixed background
(Bouillet et al., 1999). Further, unlike the vast majority of the BH3-
only proteins, Bim interacts with and sequesters all antiapoptotic
proteins (Chen et al., 2005).
Similar to mice lacking antiapoptotic Bcl-2members, mice lack-
ing Flip die in utero, and overexpression of Flip in lymphocytes has
yielded conflicting results, none of which led to an autoimmune-
diseasephenotype.Thus, thevastmajorityof studieshave focused
on Fas. A previous study showed that Faslpr/lpr mice expressing
a human BCL2-Ig minigene display modest splenomegaly and
profound lymphadenopathy (Reap et al., 1995). Because recent
Figure 1. Apoptosis-Related Gene Expression Profiles of SLE and
Healthy Control PBMC Subsets
CFLAR,MCL1, andBCL2A1 gene expression in sorted CD33+myeloid cells (A)
and CD4+ T cell (B) and CD19+ B cell (C) subsets from healthy controls (HC)
and SLE patients. Red, black, and green indicate that the gene expression is
greater than, equal to, or less than the mean amount of expression of all sam-
ples. Myxovirus resistance-1 (MX1) has been shown previously to correlate
with SLE disease activity (Bennett et al., 2003).
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Loss of Bim and Fas Leads to SLEFigure 2. Development of Splenomegaly and Lymphadenopathy in Mice Deficient for Bim and Fas
(A) Increased splenic cellularity inBcl2l11/Faslpr/lprmice. Splenic cells were isolated fromWT (n = 8),Bcl2l11/ (n = 20), Faslpr/lpr (n = 17), andBcl2l11/Faslpr/lpr
(n = 27) mice and counted so that the total cell number could be obtained. The values represent the mean ± SEM and were compared by student’s t test.
(B) Abnormal splenic architecture in Bcl2l11/Faslpr/lpr mice. A representative photomicrograph of spleens isolated from female WT, Bcl2l11/, Faslpr/lpr, and
Bcl2l11/Faslpr/lpr mice and stained with hematoxylin and eosin is shown. Scale bars represent 100 mm.
(C) Increased lymph node cellularity in Bcl2l11/Faslpr/lpr mice. Single lymph nodes were isolated from WT (n = 2), Bcl2l11/ (n = 4), Faslpr/lpr (n = 4), and
Bcl2l11/Faslpr/lpr mice (n = 5) and counted by trypan blue exclusion so that the total cell number could be obtained.
The values represent the mean ± SEM and were compared by student’s t test. * indicates p < 0.0007 as compared to theWT, y indicates p < 0.0007 as compared
to Bcl2l11/, and z indicates p < 0.005 as compared to Faslpr/lpr.studieshave suggested that the function ofBcl-2andBimmight be
linkedas loss ofBim rescues thephenotype inBcl2/mice (Bouil-
let et al., 2001) and because overexpression of Bcl-2 has been
shown to lead to splenomegaly and lymphadenopathy in Faslpr/lpr
mice, we generated Faslpr/lpr mice lacking Bim. Faslpr/lpr mice on
C57BL/6 background were intercrossed with Bcl2l11/ mice on
C57BL/6 background (Bcl2l11/Faslpr/lpr), which is normally resis-
tant to SLE-like disease. Bcl2l11/Faslpr/lprmice were born at the
expected Mendelian frequency and displayed no overt develop-
mental defects. By 16 weeks of age, Bcl2l11/Faslpr/lprmice had
developed severe splenomegaly and lymphadenopathy (Figures
2A and 2C and Figure S1 available online). This increase in spleno-
cytenumberwasaccompaniedbyadistinctalteration in splenicar-
chitecturecharacterizedbyadecreasedamount of redpulp andan
increased expansion ofwhite pulp (Figure 2B). These data suggest
that Bim and Fas act synergistically to maintain the size and
architecture of spleen and LN.
Abnormal B Lymphocyte Development
in Bcl2l11/Faslpr/lpr Mice
Ensuring the proper development, activity, and deletion of hema-
topoietic cells is essential in preservation of tolerance. Because
Bim and Fas have been shown to play an important role in main-
taining B cell numbers, preventing autoreactive B cells, and
suppressing the development of autoimmune disease (Bouillet
et al., 1999; Enders et al., 2003; Hutcheson et al., 2005; Laouar
et al., 2000; Pasqualetto et al., 2005; Sobel et al., 1991), we
examined the effect of concomitant loss of Bim and Fas on B
cell development. The number of B cells wasmarkedly increased
in both the spleen and lymph nodes (LNs) of Bcl2l11/Faslpr/lpr
mice. Splenic CD19+ B cells were increased by 4.3-fold over
wild-type (WT) mice, by 1.8-fold over Bcl2l11/ mice, and by
3.6-fold over Faslpr/lpr mice (Figure 3A). In the lymph nodes,
CD19+ B cells were increased by 2.2-fold over WT mice and
Bcl2l11/ mice as compared to Bcl2l11/Faslpr/lpr mice; how-
ever, therewasnodifference in the total numberofBcells in lymph
nodes of Bcl2l11/Faslpr/lpr and Faslpr/lprmice (Figure S2A).
Bcl2l11/Faslpr/lpr mice displayed an increase in the number
of immature transitional (T1, T2) B cells as well as mature follic-
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pared to WT, Bcl2l11/, or Faslpr/lpr mice (Figures 3C and 3D).
These data coincided with a perturbation of the T1:Follicular B
cell ratio (Figure 3C–3G). Furthermore, splenic B cells that
encounter antigens can differentiate into plasmablasts, and
eventually into antibody-producing plasma cells. Remarkably,
plasmablast numbers in spleen of Bcl2l11/Faslpr/lpr mice had
increased by 30.0-fold as compared to those of WT mice. The
number of plasmablasts in Bcl2l11/Faslpr/lpr spleens was
also increased over the number of plasmablasts in Bcl2l11/
(2.0-fold) and Faslpr/lpr (4.0-fold) mice (Figure 3H).
Given that B cell development is altered by the concomitant
loss of Bim and Fas, we observed that the expression of major
histocompatibility complex (MHC) class II was increased in
Bcl2l11/Faslpr/lpr mice (Figure 3B and Figure S2B) over WT
(1.5-fold in spleen, 3.0-fold in LN), Bcl2l11/ (7.4-fold in spleen,
5.5-fold in LN), and Faslpr/lpr (1.4-fold in spleen, no difference in
LN) mice. Furthermore, FcRgII/III receptor expression was
enhanced in Bcl2l11/Faslpr/lpr mice over that of WT (1.9-fold
in spleen, 2.7-fold in LN), Bcl2l11/ (3.0-fold in spleen, 1.9-
fold in LN) and Faslpr/lpr (1.7-fold in spleen, 3.6-fold in LN) mice
(Figure 3B and Figure S2B). These data suggest that Bim and
Fas might be equally vital for preserving the number of B cell
subsets, but Fas might be more vital in limiting antigen presenta-
tion by B cells in spleen and LN.
Increased T Lymphocyte Populations
in Bcl2l11/Faslpr/lpr Mice
Although B lymphocytes are clearly critical in the production of
the autoantibodies found in SLE, T lymphocytes are required
for affinity maturation, isotype switching, and memory B cell
formation (Sherriff et al., 2004). Because Bim (Strasser, 2005)
and Fas (Cohen and Eisenberg, 1991) play a crucial role in the
maintenance of T cells, we examined the T cell populations in
Bcl2l11/Faslpr/lpr mice as compared to single-deficient mice.
Bcl2l11/Faslpr/lpr mice showed an increase in T cell subpopu-
lations in spleen (Figure 4A) and lymph nodes (Figure S3A),
including CD4+, CD8+, central memory (CD4+CD44+CD62Lhi),
and effector memory (CD4+CD44+CD62Llow) T cells (Figure 4B
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a reduced amount of naive T cells (CD4+CD44lowCD62Lhi) as
compared toBcl2l11/ andWTmice, whereas there was no dif-
ference in the number of these cells as compared to Faslpr/lpr
mice (Figure 4B and Figure S3B). Taken together, the increase
in both central and effector memory T cells and the decrease
in naive T cells in Bcl2l11/Faslpr/lpr mice suggest an overall in-
crease in activation of Bcl2l11/Faslpr/lpr T cells. Despite the
marked increase in splenocytes in Bcl2l11/Faslpr/lpr mice (Fig-
ure 2), there was no difference in the number of T regulatory
(Treg) cells (CD4+CD25+FoxP3+) as compared to WT,
Bcl2l11/, or Faslpr/lpr mice (Figure S4A). Bcl2l11/Faslpr/lpr
mice also displayed a defect in the deletion and removal of po-
tentially self-reactive T cells, as indicated by the increase in the
number of CD3+B220+ DN (CD4CD8) T cells in Bcl2l11/
Faslpr/lprmice (Figure S4B), and these cells have been previously
described in Faslpr/lpr mice (Cohen and Eisenberg, 1991). These
data suggest that Bim and Fas synergistically regulate the acti-
vation, maturation, and removal of T lymphocytes.
Loss of Bim and Fas Leads to Accumulation of Activated
Macrophages in Spleen
Although studies on SLE often focus on T and B lymphocytes,
antigen-presenting cells such as macrophages might play vital
roles in the pathogenesis of the disease. This population might
be of particular interest in the Bcl2l11/Faslpr/lpr system given
that both Bim and Fas have previously been shown to limit circu-
lating monocyte numbers as well as macrophage activation
(Brown et al., 2004; Hutcheson et al., 2005; Scatizzi et al.,
2006). There was an increase in the number of splenic and lymph
node macrophages in Bcl2l11/Faslpr/lpr mice (Figure 4C and
Figure S5A). Not only were there more macrophages in the
spleen of Bcl2l11/Faslpr/lpr mice, but these macrophages dis-
played an enhanced activation phenotype, including increased
expression of CD40, CD86, MHC class II, and FcgRII/III
(Figure 4D and Figure S5B). In contrast, the dendritic cell
population displayed only a marginal increase in markers of
activation in Bcl2l11/Faslpr/lpr mice (Figure S6A) as compared
to single-deficient mice. Further, there was only an increase in
numbers of dendritic cells in spleen (Figure 4C) but not in lymph
nodes as compared to Faslpr/lpr mice (Figure S6B). These data
suggest that Bim and Fas synergize to prevent abnormal macro-
phage accumulation and activation.
Increased Circulating Autoantibodies
in Bcl2l11/Faslpr/lpr Mice
In SLE, the presence of autoantibodies against self-antigens is
a hallmark of the disease. Because Bcl2l11/Faslpr/lpr mice
display several characteristics consistent with SLE, we exam-
ined serum for several common circulating autoantibodies in
Bcl2l11/Faslpr/lpr mice. Bcl2l11/Faslpr/lpr mice displayed
an increase over WT mice in total anti-IgM, total anti-IgG,
anti-dsDNA IgM (dsDNA: double-stranded DNA), anti-dsDNA
IgG, anti-ssDNA IgM (ssDNA: single-stranded DNA), anti-
ssDNA IgG, anti-histone, and anti-nuclear antibodies (Figures
5A–5E). Furthermore, the amounts of total anti-IgM, anti-dsDNA
IgM, anti-dsDNA IgG, anti-ssDNA IgM, anti-ssDNA IgG, anti-
histone, and anti-nuclear antibodies were increased over the
amounts in Bcl2l11/ mice, and there was also an elevationin the circulating amounts of total anti-IgG, total anti-IgM,
anti-dsDNA IgM, anti-ssDNA IgM, and anti-nuclear antibodies
over those amounts found in Faslpr/lpr mice as compared to
amounts in Bcl2l11/Faslpr/lpr mice (Figures 5A–5E). Although
Bcl2l11/Faslpr/lpr mice displayed increases in anti-DNA anti-
body amounts, these data show that the loss of Fas contributes
to the increase in class-switched IgG antibodies predominantly
over the loss of Bim. These potentially represent the autoanti-
bodies most responsible for disease pathogenesis (Figure 5).
A proteome array (Li et al., 2005; Li et al., 2007), which
examines over 85 different autoantigens, revealed that
Bcl2l11/Faslpr/lpr serum had an increase in IgM autoantibodies
specific for collagen I, ribosomal phosphoprotein P0 (P0), trans-
fer RNA (tRNA) synthetase antigen PL-7 (PL-7), dsDNA, and rat
glomerular sonicate and IgG autoantibodies specific for Scl-70
(DNA topoisomerase I), P0, histone H3 (H3), myelin basic protein
(MBP), cardiolipin, and b2-microglobulin as compared to sin-
gle-deficient or WT mice (Figure 6A). These data indicate an
increased amount of anti-nuclear, anti-cytoplasmic, and anti-
glomerular autoantibodies in Bcl2l11/Faslpr/lpr mice. Further-
more, Bcl2l11/Faslpr/lpr mice had a markedly increased
amount of deposited IgG antibody, mainly localized at the
glomerular basement membrane, as compared to WT,
Bcl2l11/, and Faslpr/lpr mice (Figure 6B). When quantitated,
Bcl2l11/Faslpr/lpr mice displayed a 9.8-fold, 1.6-fold, and 1.8-
fold increase in fluorescence intensity as compared to WT,
Bcl2l11/, and Faslpr/lpr mice, respectively (Figure 6C). The
autoantigen array (Figure 6A) and immunohistology (Figures 6B
and 6C) data indicate an increased amount of anti-glomerular
antibodies in Bcl2l11/Faslpr/lpr mice as compared to WT,
Bcl2l11/, and Faslpr/lpr mice, and this could, in part, explain
the increased severity of disease in these mice.
Increased Evidence of Renal Pathology
in Bcl2l11/Faslpr/lpr Mice
Kidneys from Bcl2l11/Faslpr/lpr mice displayed increased glo-
merular size as compared to that of WT, Bcl2l11/, or Faslpr/lpr
mice. Furthermore, the glomeruli from Bcl2l11/Faslpr/lpr mice
showedhistologicalevidenceof renaldamage, including increased
mesangial expansion, basementmembrane thickening, increased
interstitial infiltration, and loss of open capillary loops (Figure 6D).
Histological scoring of kidneydestruction (Hill et al., 2000) revealed
an 11.0-fold increase in biopsy index over WT mice, a 1.7-fold
increase over Bcl2l11/ mice, and a 3.4-fold increase over
Faslpr/lprmiceascompared toBcl2l11/Faslpr/lpr (Figure6E).There
was a marked increase in the number of CD45+ leukocytes in kid-
neys isolated from Bcl2l11/Faslpr/lpr mice as compared to WT
(4.6-fold), Bcl2l11/ (2.8-fold), or Faslpr/lpr mice (3.2-fold)
(Figure 7A). As a result, Bcl2l11/Faslpr/lpr mice displayed
a 10.2-fold increase in renal B cells (CD19+) as compared to WT
mice and an 14.8-fold and 18.4-fold increase over Bcl2l11/
and Faslpr/lprmice (Figure 7B). Furthermore, there was an increase
in glomerular proliferation in Bcl2l11/Faslpr/lprmice as displayed
by increased proliferating cell nuclear antigen (PCNA) staining
within the glomeruli (Figure 7C).
Because B cells only account for a portion of the cells infil-
trating into the kidneys of Bcl2l11/Faslpr/lpr mice, we ana-
lyzed the presence of myeloid cells. Both Bcl2l11/ and
Bcl2l11/Faslpr/lpr mice exhibited an increase in the number
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(A) Increased number of total B cells in Bcl2l11/Faslpr/lprmice. Splenic CD19+ B cells were enumerated in WT (n = 8), Bcl2l11/ (n = 20), Faslpr/lpr (n = 17), and
Bcl2l11/Faslpr/lpr (n = 27) mice by flow cytometry as described in the Experimental Procedures.
(B) Bcl2l11/Faslpr/lpr splenic B cells are more activated. Splenic CD19+ B cells were analyzed for expression of activationmarkers MHC class II and FcRgII/III by
flow cytometry as described in the Experimental Procedures.
(C and D) Increase in transitional B cells in Bcl2l11/Faslpr/lpr spleens. T1 (B220+AA4.1+CD23) and T2 (B220+AA4.1+CD23+) transitional B cell populations were
analyzed by flow cytometry.
(E and F) Increase in marginal zone and follicular B cells in Bcl2l11/Faslpr/lpr spleens. Marginal zone (MZ, CD19+CD21+CD23) and follicular (Fo,
CD19+CD21+CD23+) B cell populations were analyzed by flow cytometry.
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Loss of Bim and Fas Leads to SLEFigure 4. Loss of Bim and Fas Results in Increase in Multiple Hematopoietic Cell Populations
(A and B) Increased accumulation of T cells in Bcl2l11/Faslpr/lpr mice. Splenic CD4+ and CD8+ T cell populations, as well as CD4+ memory T cells and naive T
cells, were enumerated inWT (n = 8),Bcl2l11/ (n = 20), Faslpr/lpr (n = 17), andBcl2l11/Faslpr/lpr (n = 27) mice by flow cytometry as described in the Experimental
Procedures.
(C and D) Accumulation of hyperactivated macrophages in Bcl2l11/Faslpr/lpr spleens. The number of macrophages in WT (n = 8), Bcl2l11/ (n = 20), Faslpr/lpr
(n = 17), and Bcl2l11/Faslpr/lpr (n = 27) spleens was determined by flow-cytometry analysis. These cells were further characterized for the determination of their
expression of activation markers.of macrophages surrounding the glomeruli as compared to WT
and Faslpr/lpr mice (Figures 7D–7F). Histological scoring of anti-
F4/80-stained sections confirmed that although there was no
difference between the macrophage populations in Bcl2l11/
and Bcl2l11/Faslpr/lpr kidneys, Bcl2l11/Faslpr/lpr mice dis-
played a 2.5-fold increase in the combined macrophage index
over Faslpr/lpr mice, and WT mice displayed no macrophage in-
dex at all (Figure 7D). This increase in macrophage index in
Bcl2l11/ and Bcl2l11/Faslpr/lpr mice was primarily a result
of an increased presence of periglomerular macrophages.
These data were further confirmed by flow cytometry, which re-
vealed that the number of renal macrophages in
Bcl2l11/Faslpr/lpr mice was similar to that of Bcl2l11/
mice but was increased by 4.4-fold over WT and 16.5-fold
over Faslpr/lpr mice (Figure 7F). Although these data showthat there is an increase in the number of macrophages
in Bcl2l11/Faslpr/lpr and Bcl2l11/ kidneys, there was no
increase in the number of CD11c+ dendritic cells, suggesting
that macrophages were the key antigen-presenting cells in
the kidneys of Bcl2l11/Faslpr/lpr mice. Further, there was no
increase in any T cell population in Bcl2l11/Faslpr/lpr,
Bcl2l11/, Faslpr/lpr or WT kidneys. These data suggest that
macrophages constituted a considerable portion of the cells
found to be infiltrating into Bcl2l11/ and Bcl2l11/Faslpr/lpr
kidneys and reveal a critical role for Bim in the maintenance
of renal macrophage homeostasis.
A low amount of apoptosis occurs in normal kidneys. Moreover,
the few apoptotic cells in the kidney are rapidly phagocytosed and
removed (Baker et al., 1994; Hughes et al., 2004). Surprisingly, de-
spite the increase in macrophages in kidneys ofBcl2l11/Faslpr/lpr(G) Altered T1:follicular B cell ratio in Bcl2l11/Faslpr/lpr mice. A ratio was devised by division of the number of T1 transitional B cells by the number of follicular
B cells.
(H) Enhanced number of plasmablasts inBcl2l11/Faslpr/lpr spleens. The splenic plasmablast (CD138+) population was analyzed by flow cytometry as described
in the Experimental Procedures.
The values represent the mean ± SEM and were compared by student’s t test. * indicates p < 0.04 as compared to the WT, y indicates p < 0.02 as compared to
Bcl2l11/, and z indicates p < 0.006 as compared to Faslpr/lpr.
Immunity 28, 206–217, February 2008 ª2008 Elsevier Inc. 211
Immunity
Loss of Bim and Fas Leads to SLEFigure 5. Elevated Amounts of Circulating Autoantibodies in Bcl2l11/Faslpr/lpr Serum
(A) Increased total circulating autoantibodies in Bcl2l11/Faslpr/lpr serum. Serum were isolated from WT (n = 8), Bcl2l11/ (n = 20), Faslpr/lpr (n = 17), and
Bcl2l11/Faslpr/lpr (n = 27) mice. Total IgM and total IgG ELISAs were run according to the manufacturer’s specifications (Bethyl Laboratories).
(B) Increased circulating dsDNA autoantibodies in Bcl2l11/Faslpr/lpr serum. Anti-dsDNA IgM and anti-dsDNA IgG ELISAs were examined according to the
manufacturer’s specifications (Alpha Diagnostics).
(C) Increased circulating ssDNA autoantibodies in Bcl2l11/Faslpr/lpr serum. Anti-ssDNA IgM and anti-ssDNA IgG ELISAs were run according to the manufac-
turer’s specifications (Alpha Diagnostics).
(D) Loss of Fas leads to an increase in circulating anti-histone antibodies in serum. Total anti-histone ELISAs were examined according to the manufacturer’s
specifications (Alpha Diagnostics).
(E) Increased circulating anti-nuclear antibodies inBcl2l11/Faslpr/lpr serum. Total anti-nuclear antibody ELISAs were examined according to themanufacturer’s
specifications (Alpha Diagnostics).
All values represent the mean ± SEM and were compared by student’s t test. * indicates p < 0.01 as compared to the WT, y indicates p < 0.01 as compared to
Bcl2l11/, and z indicates p < 0.01 as compared to Faslpr/lpr.
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Loss of Bim and Fas Leads to SLEFigure 6. Bcl2l11/Faslpr/lpr Mice Display
Evidence of Increased Circulating and De-
posited Autoantibodies, Resulting in Renal
Damage
(A) Serum proteome array reveals additional
autoantibodies. Serum were isolated from WT
(n = 4), Bcl2l11/ (n = 4), Faslpr/lpr (n = 4), and
Bcl2l11/Faslpr/lpr (n = 4) mice. Proteome arrays
were performed as previously described (Li et al.,
2005; Li et al., 2007). The data were compared
by one-way ANOVA for IgM (Cy3) or IgG (Cy5) as
described in the Experimental Procedures.
(B) Bcl2l11/Faslpr/lpr mice display more severe
deposition of immune complexes on the glomeruli.
Representative photomicrographs of immune-
complex deposition in kidneys are shown. Kidneys
were isolated from 16- to 20-week-old WT
(n = 8), Bcl2l11/ (n = 20), Faslpr/lpr (n = 17), and
Bcl2l11/Faslpr/lpr (n = 27) mice and frozen in
OCT media. Sections were cut and slides were
stained with conjugated anti-IgG antibody as de-
scribed in the Experimental Procedures.
(C) Graphic representation of increased immune-
complex deposition in Bcl2l11/Faslpr/lpr mice.
Kidneys were isolated and photographed as de-
scribed above. Kidney sections were scored on
a 0–4 scale on the basis of fluorescence intensity
as compared to background as described in the
Experimental Procedures.
(D) Histopathological signs of renal damage. Rep-
resentative photomicrographs of kidneys isolated
WT (n = 8), Bcl2l11/ (n = 20), Faslpr/lpr (n = 17),
and Bcl2l11/Faslpr/lpr (n = 27) mice. All images
were taken at 4003 total magnification. Scale
bars represent 50 mm.
(E) Increased renal biopsy index scores in
Bcl2l11/Faslpr/lpr mice. Kidneys were isolated
and treated as described above and scored by
a pathologist blinded to the study as described
in Materials and Methods. The Biopsy Index is an
average derived by dividing the sum of the scores
by the number of criteria, as previously described
(Hill et al., 2000).
All values represent the mean ± SEM and were
compared by student’s t test. * indicates p < 0.05
as compared to the WT, y indicates p < 0.05 as
compared to Bcl2l11/, and z indicates p < 0.05
as compared to Faslpr/lpr.mice, there was an increase in TUNEL+ cells in Bcl2l11/Faslpr/lpr
glomeruli (Figure S7A). The average number of TUNEL+ cells per
glomerulus is increased by 4.3-fold, 1.9-fold, and 2.2-fold in
Bcl2l11/Faslpr/lpr mice as compared to WT, Bcl2l11/, and
Faslpr/lpr mice (Figure S7B). Interestingly, the increase in apoptosis
coincided with enhanced numbers of proliferating cells in the glo-
meruli of Bcl2l11/Faslpr/lpr mice (Figure 7C). Although these
in vivo data suggest that phagocytosis of apoptotic debris is de-
creased in Bcl2l11/Faslpr/lprmice, bone-marrow-derived macro-
phages from young Bcl2l11/Faslpr/lpr mice (6–8 weeks old)
phagocytosed apoptotic thymocytes and opsonized beads equally
asWT,Bcl2l11/, or Faslpr/lpr cells (Figure S8). These data suggest
that the pathogenesis of SLE or the milieu of the kidney might be
a crucial determinant of the phagocytic ability of macrophages.DISCUSSION
SLE is a complex, heterogeneous disease that can result from
a variety of single or combined hematopoietic defects, with
a strong influence from genetic elements. The genetic contribu-
tion of murine lupus can be divided into lupus-prone strains
(MRL, NZB, NZM2410, and BXSB), which all contain loci which
predispose for certain characteristics of SLE (e.g., autoantibody
production, early mortality, and kidney damage) (Mohan, 2001),
and lupus-resistant strains (BALB/c, C3H, and C57BL/6), which
lack these loci. It has been shown that SLE can be established on
resistant backgrounds by the insertion of specific loci from
lupus-prone backgrounds, as is the case with the establishment
of the Sle1, Sle2, and Sle3 loci from the NZM2410/NZW
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2007). Thus, our findings that Bcl2l11/Faslpr/lpr mice develop
SLE-like disease details a mechanism for investigating the spon-
taneous development of SLE-like disease in mice as a result of
the loss of only these two proapoptotic genes. The development
of SLE in Bcl2l11/Faslpr/lpr mice is a result of a combination of
hematopoietic cell defects, including a hyperactivation of T and
B lymphocytes as well as macrophages. Furthermore, although
our data indicate that singular loss of Bim or Fas can contribute
to some aspects of SLE-like disease on the C57BL/6
Figure 7. Increased Infiltration of Leukocytes into Kidneys of Bcl2l11/Faslpr/lpr Mice
(A) Increased CD45 expression in Bcl2l11/Faslpr/lpr mice. Kidneys were isolated from WT (n = 12), Bcl2l11/ (n = 8), Faslpr/lpr (n = 4), and Bcl2l11/Faslpr/lpr
(n = 5) mice as described in the Experimental Procedures. Cells were stained as described in the Experimental Procedures.
(B) Enhanced number of B cells in Bcl2l11/Faslpr/lpr kidneys. Cells were isolated as described above and stained as described in the Experimental Procedures.
(C) Increased glomerular proliferation inBcl2l11/Faslpr/lprmice. Kidneys were isolated as described above and scored for the percentage of PCNA positivity per
glomerulus by a pathologist blinded to the study.
(D) Increasedmacrophage index inBcl2l11/ andBcl2l11/ Faslpr/lprmice. Kidneys were isolated and scored for the presence of macrophages by a pathologist
blinded to the study as described in Experimental Procedures.
(E) Increased number of macrophages surrounding the glomeruli. Representative photomicrographs of infiltrating macrophages in kidneys are shown. Kidneys
isolated fromWT, Bcl2l11/, Faslpr/lpr, and Bcl2l11/Faslpr/lprmice were stained with anti-F4/80 antibody (clone: BM8, Caltag) as described in the Experimental
Procedures. Scale bars represent 50 mm.
(F) Flow cytometry reveals an increase in kidney macrophage numbers. Cells were isolated from kidneys and stained as described above.
The values represent the mean ± SEM and were compared by student’s t test. * indicates p < 0.05 as compared to the WT, y indicates p < 0.05 as compared to
Bcl2l11/, and z indicates p < 0.05 as compared to Faslpr/lpr mice.
214 Immunity 28, 206–217, February 2008 ª2008 Elsevier Inc.
Immunity
Loss of Bim and Fas Leads to SLEbackground, they also specifically implicate Fas as amediator of
B cell class switching and antigen presentation and Bim as a po-
tent regulator of renal macrophage infiltration, suggesting a syn-
ergistic role for the intrinsic and extrinsic apoptosis pathways in
the development of murine SLE and providing a model of SLE on
the C57BL/6 background that requires only 4months to develop.
Although it has been suggested that Fas does not play a role in
the BCR-induced deletion of transitional B cells (King and Mon-
roe, 2000), the increase in T1 B cells in Bcl2l11/Faslpr/lpr mice
as compared toBcl2l11/mice suggests that the loss of Fas en-
hances the build up of T1 B cells in Bcl2l11/Faslpr/lpr mice. A
lackof apoptosis in T1Bcells has been implicated in thedevelop-
ment of lupus in the New Zealand black (NZB) model, and it has
been suggested that this is an effect of increased Bcl-2 expres-
sion (Roy et al., 2005). Because Bcl-2 is an antiapoptotic protein
and a binding partner of Bim, loss of Bim could result in higher
amounts or higher concentrations of Bcl-2. An increase in the ra-
tio of immature transitional T1 tomature follicularB cells suggests
that Bcl2l11/Faslpr/lpr mice have a defect in the deletion of B
cells, and potentially a defect in B cell anergy, as has been previ-
ously reported in Bcl2l11/ mice (Oliver et al., 2006). Further-
more, a loss of tolerance in early B cell development has been
associated with the development of SLE in humans (Yurasov
et al., 2005). Given that SLE ismediated by autoantibodies, an in-
crease in plasmablasts, as in Bcl2l11/Faslpr/lpr mice, would
allow for greater production of autoantibodies and increase the
severity of SLE. This increase in plasmablasts and the activated
B cell phenotype would explain the high titer of autoantibodies
found in Bcl2l11/Faslpr/lpr mice.
Although B lymphocytes are critical in the production of the
autoantibodies found in SLE, T lymphocytes are required for
affinity maturation, isotype switching, and memory B cell forma-
tion (Sherriff et al., 2004). The increase in both central and effec-
tor memory T cells suggests an enhanced state of activation in
Bcl2l11/Faslpr/lpr mice that correlates with the hyperactivated
B cell phenotype observed in both spleen and lymph nodes. It
has recently been shown that the numbers of T regulatory cells
are reduced in mouse models of SLE as well as in human
patients (Hsu et al., 2006); correspondingly, we show that T reg-
ulatory cell numbers in Bcl2l11/Faslpr/lpr mice were not differ-
ent than those in WT, Bcl2l11/, or Faslpr/lpr mice. Accordingly,
the titers of IL-17 inBcl2l11/Faslpr/lpr serumwere not increased
(J.H. and H.P., unpublished data). Bcl2l11/Faslpr/lpr mice also
display a defect in the deletion and removal of potentially self-
reactive T cells, as indicated by the increase in the number of
CD3+B220+ DN T cells in Bcl2l11/Faslpr/lpr mice.
SLE is characterized by circulating autoantibodies, especially
autoantibodies specific for anti-nuclear antigens (Tan et al.,
1966). In Bcl2l11/ and Faslpr/lpr mice (Figures 5A–5E), there is
aconsistent increase inboth total IgMand total IgGautoantibodies,
as well as other antibodies, as determined by enzyme-linked
immunosorbent assay (ELISA). Bcl2l11/Faslpr/lpr mice also
displayed an increase in the expression of autoantibodies found
in patients with lupus as compared to WT, Bcl2l11/, or Faslpr/lpr
mice, as determined by a serum proteome array. Furthermore,
Bcl2l11/Faslpr/lpr mice displayed a higher amount of autoanti-
bodiesspecific for rat glomerular sonicate, further suggestingan in-
crease in glomerular autoantibodies in Bcl2l11/Faslpr/lpr mice.
The overall profile generated by these proteome array data ismore similar between Bcl2l11/Faslpr/lpr and Faslpr/lpr mice as
compared to Bcl2l11/ or WT mice. These data suggest that the
combined hematopoietic defects in Bcl2l11/Faslpr/lpr mice con-
tribute to the loss of tolerance and the development of SLE-like
characteristics. In addition to the increased titer of circulating IgM
and IgG antibodies,Bcl2l11/Faslpr/lprmice also have an increase
in the amount of IgGdeposited in kidneys, whichmight be a conse-
quenceof increasedBcell presence in thekidney.Thedepositionof
immune complexes at the basement membrane of the kidney is
consistent with increased renal destruction in Bcl2l11/Faslpr/lpr
mice. Collectively, these data demonstrate that the deficiency in
Bim and Fas alone induce a rapid and severe lupus-like phenotype
on a normally autoimmune-resistant background.
EXPERIMENTAL PROCEDURES
Mice
Bcl2l11/ (C57BL/6) mice were a kind gift from A. Strasser (Walter and Eliza
Hall Institute, Melbourne, Australia) (Bouillet et al., 1999). Congenic control
(C57BL/6, WT) and Fas mutant Faslpr/lpr (B6.MRL-Faslpr/J) mice were pur-
chased from the Jackson Laboratory (Bar Harbor, ME). Bcl2l11/Faslpr/lpr
mice on the C57BL/6 background were established at Saint Louis University
by the crossing of Bcl2l11/ and Faslpr/lpr mice. Mice used for this study
were 16- to 20-week-old females maintained in a stress-free environment.
The Animal Care and Use Committee at Saint Louis University approved all
experiments on mice.
Study Participants
The study protocol was approved by the Internal Review Board of the Univer-
sity of Texas Southwestern Medical Center (UTSW). Fourteen SLE patients
and matched healthy controls were recruited from the UTSW registry. All
patients fulfilled at least four of the 11 American College of Rheumatology
classification criteria for SLE. Detailed clinical characteristics of study subjects
along with their medications were collected for each patient as described (Han
et al., 2005). Disease activity at time of blood acquisition was determined with
the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score
(Bombardier et al., 1992), and patients were further classified according to
disease severity where SLEDAI less than 6 was considered mild and SLEDAI
more than 6 was moderate to severe.
Cell Acquisition and Sorting
Peripheral bloodwas collected in heparinized tubes and processed. Peripheral
blood mononuclear cells (PBMCs) were isolated with density-gradient centri-
fugation over Ficoll-Hypaque, and cells were labeled with fluorochrome-
conjugated antibodies including CD33, CD3, CD4, andCD19 (BDBiosciences,
PharMingen) and sorted with a 6+ color analyzer and sorter MoFlo Flow
Cytometer (DakoCytomation) into individual subpopulations of CD19+ B cells,
CD33+ myeloid cells, and CD4+ T cells. Not all subsets were collected for all
samples. Purity of the individual populations after sorting was verified to be
greater than 95%.
RNA Extraction and Chip Hybridization
RNA was extracted with Trizol (Invitrogen) and further purified by RNeasy
columns (QIAGEN). RNA integrity and yieldwas confirmed byBioanalyzer (Agi-
lent Technologies). Complementary RNA (cRNA) probes were generated (Am-
bion), and cRNA was hybridized to Affymetrix HG-U133A GeneChips with ad-
herence to stringent quality control criteria for chip hybridization (Expression
Analysis Technical Manual, Affymetrix) for all samples.
Data Processing
Genechip Operating Software v1.1 by Affymetrix was employed for the gener-
ation of expression values,and data was imported into GeneSpring v. 7.3 soft-
ware (Agilent Technologies). The data were normalized, filtered for flags and
expression, and subjected to statistical analysis (one-way analysis of variance
[ANOVA]). Hierarchical clustering was performed with Cluster and data was
visualized with TreeView (EisenSoftware).
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Kidneys were isolated and prepared for histological analysis by being cut in
half laterally and fixed in 10% formalin. Specimens were then embedded in
paraffin, sectioned (3 mm), and stained with hematoxylin and eosin (H&E) or pe-
riodic acid-Schiff (PAS) stain. All sections were scored by a pathologist blinded
to the study (G.K.H.) on the basis of a modification of a previously reported
scoring system (Hill et al., 2000). Paraffin embedded sections were incubated
with Dako target retrieval solution prior to the staining for F4/80 as previously
described (Hutcheson et al., 2005). Anti-F4/80-stained kidneyswere scored by
a pathologist blinded to the study for the presence of macrophages in the
glomeruli, periglomerular space, cortex, medulla, and lymphoid infiltrate.
Each region was scored on a scale from 0 to 3. An overall macrophage index
was determined by addition of the values from each region and division by the
number of regions (macrophage index = total score/5). Kidneys were also
embedded in optimal cutting temperature (OCT) embedding media, snap
frozen, sectioned (3 mm), and stained for IgG. The sections were incubated
with rhodamine-red-conjugated donkey anti-mouse IgG (Jackson ImmunoRe-
search Laboratories, West Grove, PA) at 37C for 30 min in a moist box.
Images taken at 4003 were scored from 0 to 4 on the basis of fluorescence
intensity as compared to the background for the sample. For apoptotic-
body analysis, paraffin-embedded kidney sections were stained for TUNEL
(Roche Biochemical, Indianapolis, IN, in situ death detection kit). Three differ-
ent areas per kidney of TUNEL+ cells were identified at 4003 power. TUNEL
scores were obtained by calculation of an average number of TUNEL+ cells/
glomerulus in five glomeruli. Spleens were isolated and fixed in 10% parafor-
maldehyde. Fixed specimens were embedded in paraffin and sectioned.
Sections were stained with H&E, and photomicrographs were taken at 2003
magnification for the determination of splenic architecture. All photographs
were taken on a Nikon (Tokyo, Japan) microscope equipped with the Nikon
digital camera DMX1200.
Measurement of Autoantibody Titers
Peripheral blood was isolated from mice by cardiac stick and allowed to clot,
and serum was separated out by centrifugation. Serum was screened for total
IgM or IgG (Bethyl Laboratories, Montgomery, TX) and for autoantibodies to
dsDNA (IgM and IgG), ssDNA (IgM and IgG), histones (total Ig), and anti-
nuclear antibodies (ANAs, total Ig) with ELISA, as described by the manufac-
turer (Alpha Diagnostics International, San Antonio, TX).
Immunophenotyping
Spleen, cervical lymph nodes, and kidneys were isolated from 16- to 20-week-
old mice and prepared as previously described (Hutcheson et al., 2005). Cells
were then stained for 30minwith fluorochrome-conjugated antibodies specific
to CD3, CD4, CD8, CD11b, CD11c, CD19, CD21, CD23, CD25, CD40, CD44,
CD45, CD62L, CD69, CD86, CD138 (Syndecan-1), Gr-1, NK1.1, TCRb, AA4.1
(BD Biosciences, PharMingen), CD45R (B220), F4/80 (BM8) (Invitrogen, Cal-
tag, Carlsbad, CA), or FoxP3 (eBioscience, San Diego, CA). After the staining,
cells were washed and fixed as previously described (Hutcheson et al., 2005).
For the performance of intracellular FoxP3 staining, after fixation, cells were
permeabilized with 0.3% saponin for 15 min prior to antibody staining, and
then antibody was added for 30 min. Cells were then washed with 0.1% sapo-
nin. Data were acquired and analyzed as previously described (Hutcheson and
Perlman, 2007).
Glomerular Proteome Array
Serum from WT, Bcl2l11/, Faslpr/lpr, and Bcl2l11/Faslpr/lpr (all n = 4) mice
were analyzed by a proteome array (Li et al., 2005; Li et al., 2007). The raw
data were normalized to multiple technical controls on each of the 16 arrays.
Antigen spots that showed no fluorescence were assigned a signal intensity
of 0 and designated as missing values in the subsequent statistical analysis,
which was conducted with a one-way ANOVA separately on the IgM (Cy3)
and IgG (Cy5) datasets. Pair-wise comparisons were conducted as follows:
Bcl2l11/Faslpr/lpr versus WT, Bcl2l11/Faslpr/lpr versus Bcl2l11/,
Bcl2l11/Faslpr/lpr versus Faslpr/lpr Bcl2l11/ versus WT, and Faslpr/lpr versus
WT. The comparisons of interest were Bcl2l11/Faslpr/lpr versus Bcl2l11/
andBcl2l11/Faslpr/lpr versus Faslpr/lpr. Significant differences in autoantibody
profile were identified with p% 0.05 for the two comparisons of interest. The
significant autoantibody profile differenceswere then placed into three groups:
216 Immunity 28, 206–217, February 2008 ª2008 Elsevier Inc.only changed in Bcl2l11/Faslpr/lpr/ versus Bcl2l11/, only changed in
Bcl2l11/Faslpr/lpr versus Faslpr/lpr, and changed in both comparisons.
Statistical Analysis
Results were expressed as the mean ± standard error of the mean (SEM).
Differences between groups were analyzed with Student’s t tests unless
otherwise noted. Correlations were determined by Spearman rank order.
Supplemental Data
Eight figures are available at http://www.immunity.com/cgi/content/full/28/2/
206/DC1/.
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